These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
A CNS targeting prodrug strategy for nuclear receptor modulators-merged.pdf (2.6 MB)
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 20.05.2020 and posted on 20.05.2020by Skylar Ferrara, Thomas Scanlan
Neurodegenerative diseases lack a breadth of treatment options due, in part, to the known difficulties associated with a drug’s passage across the blood-brain barrier. In this study, we provide a blueprint for how to get drug-like structures which feature carboxylic acid motifs across the blood-brain barrier, while attenuating their peripheral exposure using a chemical prodrug strategy. This prodrug strategy utilizes endogenous fatty-acid amide hydrolase expressed in the CNS to cleave and release parent drugs for CNS drug action to commence. In particular, we demonstrate the successes and limitations of this prodrug strategy within a series of nuclear receptor modulators, which have shown promise as potential therapeutics for neurodegenerative diseases.
The authors declare the following competing financial interest(s): S.J.F. and T.S.S. are inventors of a licensed patent application claiming central nervous system-penetrating prodrugs of nuclear receptor modulators and their uses. T.S.S. is a founder of Autobahn Therapeutics.